Journal Scans
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Pralatrexate Effective in Relapsed/Refractory Peripheral T-Cell Lymphoma
OA O'Connor, B Pro, L Pinter-Brown, N Bartlett, L Popplewell, B Coiffier, MJ Lechowicz, KJ Savage, AR Shustov, C Gisselbrecht, E Jacobsen, PL Zinzani, R Furman, A Goy, C Haioun, M Crump, JM Zain, E Hsi, A Boyd, S Horwitz
Yes
20110018
2011 Jan 18
J Clin Oncol
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
J Clin Oncol. 2011 Jan 18;[Epub Ahead of Print], OA O'Connor, B Pro, L Pinter-Brown, N Bartlett, L Popplewell, B Coiffier, MJ Lechowicz, KJ Savage, AR Shustov, C Gisselbrecht, E Jacobsen, PL Zinzani, R Furman, A Goy, C Haioun, M Crump, JM Zain, E Hsi, A Boyd, S Horwitz
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Peripheral T-cell lymphoma (PTCL) accounts for 10% to 15% of newly diagnosed cases of non-Hodgkin’s lymphoma in North America. Chemotherapy regimens for PTCL are derived from those for B-cell lymphomas, but PTCL is more likely to be resistant to chemotherapy, and outcomes are generally inferior to those seen in patients with B-cell lymphomas. Thus, new treatment options are needed for patients with PTCL, especially for those with recurrent or refractory disease, who generally have a poor response...
